Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was TWD 473.37 million compared to TWD 440.12 million a year ago. Net income was TWD 148.16 million compared to TWD 96.13 million a year ago. Basic earnings per share from continuing operations was TWD 1.67 compared to TWD 1.08 a year ago. Diluted earnings per share from continuing operations was TWD 1.66 compared to TWD 1.08 a year ago.